Follows people with Parkinson's disease who previously received BRT-DA01 cell therapy
Observes safety and outcomes in people with Parkinson's disease who earlier received BRT-DA01.
Plain-language title generated from the registry record
Registry title: Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Parkinson's disease who already received BRT-DA01 in the earlier Phase 1 study MSK-DA01-101. No new treatment is given in this study.
- Age
- 50 to 78 years
- Sex
- All sexes can join.
- Earlier treatment
- Must have received BRT-DA01 in study MSK-DA01-101 and completed or stopped that study.
Main reasons for not taking part
- The record lists no exclusion criteria.
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 78 years old?
Source: NCT05897957, who can take part
Where in Canada
- Toronto Western HospitalToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- BlueRock Therapeutics
- Trial code
- NCT05897957
- Record updated
- 12 April 2024
- Original description
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.Read full original descriptionShow less
Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01, a Human Embryonic Stem Cell-Derived Midbrain Dopaminergic Neuronal Cell Therapy
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
Inclusion: Subject received BRT-DA01 in Study MSK-DA01-101 (ie, parent study) and will have completed or discontinued the parent study; Subject must be willing and able to provide written informed consent for the BRT-DA0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures.
Exclusion: No exclusion criteria.